Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04107207 · ClinicalTrials.gov registry record · NA

Evaluating the Effects of Kombucha as a Hyperglycemic Therapeutic Agent Within Diabetic Human Subjects

A NA study, sponsored by Georgetown University.

Completed
Registry status
NA
Development phase
12
Enrollment target

NCT04107207 is a NA study that has completed, run by Georgetown University. The registered enrollment target is 12 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04107207, a NA study, has completed, sponsored by Georgetown University.

COMPLETED
Registry status
NA
Development phase
12 participants
Enrollment target

Study Summary

This study's primary objective is to determine the ability of Kombucha to impact blood sugar levels in patients with diabetes mellitus type II. The secondary objective is to determine the ability of Kombucha to impact blood pressure, and quality of life measures as measured by uniform questionnaire that includes: gut health, colds, infections, headaches, sleep, anxiety (GAD2), depression (PHQ2), skin health.

Interventions

  • DIETARY_SUPPLEMENT Ginger Kombucha
  • DIETARY_SUPPLEMENT Ginger Water

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2019-11-11
Est. Completion 2020-07-01
Phase NA

Sponsor

Georgetown University

227 total trials

What the Registry Record Tells You About NCT04107207

The ClinicalTrials.gov registry entry for NCT04107207 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Ginger Kombucha is the first listed.

NCT04107207 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04107207 about?

NCT04107207 is a clinical study titled "Evaluating the Effects of Kombucha as a Hyperglycemic Therapeutic Agent Within Diabetic Human Subjects". This study's primary objective is to determine the ability of Kombucha to impact blood sugar levels in patients with diabetes mellitus type II. The secondary objective is to determine the ability of Kombucha to impact blood pressure, and quality of life measures as measured by uniform questionnaire ...

What is the current status of trial NCT04107207?

This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2019-11-11. Estimated completion is 2020-07-01.

What interventions are being tested in trial NCT04107207?

The interventions under investigation include: Ginger Kombucha (DIETARY_SUPPLEMENT), Ginger Water (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT04107207?

This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.